Login
- Titel:
Rationale and design of the PARTHENOPE trial: A two-by-two factorial comparison of polymer-free vs biodegradable-polymer drug-eluting stents and personalized vs standard duration of dual antiplatelet therapy in all-comers undergoing PCI.
- Dokumenttyp:
- Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; Journal Article
- Autor(en):
- Piccolo, Raffaele; Calabrò, Paolo; Varricchio, Attilio; Baldi, Cesare; Napolitano, Giovanni; De Simone, Ciro; Mauro, Ciro; Stabile, Eugenio; Caiazzo, Gianluca; Tesorio, Tullio; Boccalatte, Marco; Tuccillo, Bernardino; Bottiglieri, Giuseppe; Russolillo, Enrico; Di Lorenzo, Emilio; Carrara, Greta; Cassese, Salvatore; Leonardi, Sergio; Biscaglia, Simone; Costa, Francesco; McFadden, Eugene; Heg, Dik; Franzone, Anna; Stefanini, Giulio G; Capodanno, Davide; Esposito, Giovanni
- Abstract:
- BACKGROUND: Over the past few decades, percutaneous coronary intervention (PCI) has undergone significant advancements as a result of the combination of device-based and drug-based therapies. These iterations have led to the development of polymer-free drug-eluting stents. However, there is a scarcity of data regarding their clinical performance. Furthermore, while various risk scores have been proposed to determine the optimal duration of dual antiplatelet therapy (DAPT), none of them have undergone prospective validation within the context of randomized trials. DESIGN: The PARTHENOPE trial is a phase IV, prospective, randomized, multicenter, investigator-initiated, assessor-blind study being conducted at 14 centers in Italy (NCT04135989). It includes 2,107 all-comers patients with minimal exclusion criteria, randomly assigned in a 2-by-2 design to receive either the Cre8 amphilimus-eluting stent or the SYNERGY everolimus-eluting stent, along with either a personalized or standard duration of DAPT. Personalized DAPT duration is determined by the DAPT score, which accounts for both bleeding and ischemic risks. Patients with a DAPT score <2 (indicating higher bleeding than ischemic risk) receive DAPT for 3 or 6 months for chronic or acute coronary syndrome, respectively, while patients with a DAPT score ≥2 (indicating higher ischemic than bleeding risk) receive DAPT for 24 months. Patients in the standard DAPT group receive DAPT for 12 months. The trial aims to establish the noninferiority between stents with respect to a device-oriented composite end point of cardiovascular death, target-vessel myocardial infarction, or clinically-driven target-lesion revascularization at 12 months after PCI. Additionally, the trial aims to demonstrate the superiority of personalized DAPT compared to a standard approach with respect to a net clinical composite of all-cause death, any myocardial infarction, stroke, urgent target-vessel revascularization, or type 2 to 5 bleeding according to the Bleeding Academic Research Consortium criteria at 24-months after PCI. SUMMARY: The PARTHENOPE trial is the largest randomized trial investigating the efficacy and safety of a polymer-free DES with a reservoir technology for drug-release and the first trial evaluating a personalized duration of DAPT based on the DAPT score. The study results will provide novel insights into the optimizing the use of drug-eluting stents and DAPT in patients undergoing PCI.
- Zeitschriftentitel:
- Am Heart J
- Jahr:
- 2023
- Band / Volume:
- 265
- Seitenangaben Beitrag:
- 153-160
- Volltext / DOI:
- doi:10.1016/j.ahj.2023.08.001
- PubMed:
- http://view.ncbi.nlm.nih.gov/pubmed/37572785
- Print-ISSN:
- 0002-8703
- TUM Einrichtung:
- Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter (DHM) (Prof. Schunkert)
BibTeX